GC
NVO

Grimes & Company’s Novo Nordisk NVO Stock Holding History

Grimes & Company’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.09M Buy
106,242
+1,134
+1% +$48.7K 0.11% 122
2026
Q1 		$3.86M Buy
105,108
+5,488
+6% +$260K 0.11% 127
2025
Q4 		$5.07M Sell
99,620
-14,132
-12% -$723K 0.12% 111
2025
Q3 		$6.31M Sell
113,752
-11,604
-9% -$679K 0.16% 101
2025
Q2 		$8.65M Buy
125,356
+18,403
+17% +$1.25M 0.24% 87
2025
Q1 		$7.43M Buy
106,953
+3,273
+3% +$270K 0.23% 93
2024
Q4 		$8.92M Sell
103,680
-2,261
-2% -$245K 0.26% 78
2024
Q3 		$12.6M Sell
105,941
-1,300
-1% -$173K 0.34% 65
2024
Q2 		$15.3M Buy
107,241
+1,557
+1% +$206K 0.46% 51
2024
Q1 		$13.6M Buy
105,684
+2,914
+3% +$347K 0.42% 61
2023
Q4 		$10.6M Buy
102,770
+1,889
+2% +$187K 0.35% 65
2023
Q3 		$9.17M Sell
100,881
-6,091
-6% -$537K 0.35% 64
2023
Q2 		$8.66M Buy
106,972
+500
+0.5% +$40.8K 0.31% 69
2023
Q1 		$8.47M Sell
106,472
-52,852
-33% -$3.75M 0.35% 66
2022
Q4 		$10.8M Buy
159,324
+2,340
+1% +$137K 0.46% 48
2022
Q3 		$7.82M Sell
156,984
-3,106
-2% -$166K 0.41% 55
2022
Q2 		$8.92M Sell
160,090
-59,850
-27% -$3.32M 0.45% 53
2022
Q1 		$12.2M Sell
219,940
-135,706
-38% -$6.96M 0.64% 48
2021
Q4 		$19.9M Sell
355,646
-1,248
-0.3% -$67.6K 0.91% 27
2021
Q3 		$17.1M Sell
356,894
-7,424
-2% -$359K 0.75% 29
2021
Q2 		$15.3M Buy
364,318
+1,428
+0.4% +$55.4K 0.66% 38
2021
Q1 		$12.2M Buy
362,890
+40,836
+13% +$1.45M 0.59% 47
2020
Q4 		$11.2M Buy
322,054
+15,802
+5% +$546K 0.58% 48
2020
Q3 		$10.6M Sell
306,252
-90,700
-23% -$3.02M 0.68% 37
2020
Q2 		$13M Sell
396,952
-8,898
-2% -$284K 0.9% 30
2020
Q1 		$12.2M Sell
405,850
-12,364
-3% -$368K 1.12% 17
2019
Q4 		$12.1M Sell
418,214
-9,686
-2% -$268K 0.79% 29
2019
Q3 		$11.1M Buy
427,900
+3,170
+0.7% +$80.2K 0.79% 28
2019
Q2 		$10.8M Buy
424,730
+5,426
+1% +$134K 0.82% 27
2019
Q1 		$11M Buy
419,304
+8,816
+2% +$217K 0.86% 28
2018
Q4 		$9.46M Buy
410,488
+1,126
+0.3% +$25K 0.92% 22
2018
Q3 		$9.65M Buy
409,362
+16,240
+4% +$396K 0.77% 36
2018
Q2 		$9.06M Sell
393,122
-3,974
-1% -$94.4K 0.8% 37
2018
Q1 		$9.78M Sell
397,096
-306
-0.1% -$8.03K 0.95% 27
2017
Q4 		$10.7M Sell
397,402
-8,170
-2% -$208K 1.03% 23
2017
Q3 		$9.76M Sell
405,572
-6,360
-2% -$144K 1.04% 23
2017
Q2 		$8.83M Sell
411,932
-40,656
-9% -$820K 0.99% 25
2017
Q1 		$7.76M Buy
452,588
+264,098
+140% +$4.6M 0.85% 33
2016
Q4 		$3.38M Sell
188,490
-196,234
-51% -$3.56M 0.39% 70
2016
Q3 		$8M Buy
+384,724
New +$9.54M 1.07% 20
2016
Q2 		– Sell
-8,742
Closed -$237K – 220
2016
Q1 		$237K Hold
8,742
– – 0.03% 172
2015
Q4 		$254K Sell
8,742
-142
-2% -$3.93K 0.03% 165
2015
Q3 		$241K Sell
8,884
-5,558
-38% -$157K 0.03% 161
2015
Q2 		$395K Sell
14,442
-330,518
-96% -$9.29M 0.06% 122
2015
Q1 		$9.21M Buy
344,960
+20,086
+6% +$463K 2.21% 4
2014
Q4 		$6.87M Buy
324,874
+1,148
+0.4% +$25.6K 1.78% 12
2014
Q3 		$7.71M Buy
323,726
+1,100
+0.3% +$25.3K 2.02% 8
2014
Q2 		$7.45M Buy
322,626
+8,666
+3% +$191K 1.95% 9
2014
Q1 		$7.17M Sell
313,960
-500
-0.2% -$10.7K 2.01% 10
2013
Q4 		$5.81M Buy
314,460
+32,050
+11% +$559K 1.74% 22
2013
Q3 		$4.78M Buy
282,410
+32,780
+13% +$551K 1.62% 28
2013
Q2 		$3.87M Buy
+249,630
New +$4.15M 1.41% 32

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
GIM
Generate Investment Management Auckland, New Zealand $2.43B AUM 37.24% 1-Year Est. Return
CFB
Cullen/Frost Bankers San Antonio, Texas $10.1B AUM 29.18% 1-Year Est. Return

Grimes & Company's NVO Position: Q2 2026 in Review

Grimes & Company increased its Novo Nordisk (NVO) stake by 1.1% in Q2 2026, buying an estimated $48.7K and bringing the position to 106,242 shares worth $5.09M. The position accounts for 0.11% of the portfolio, ranked #122.

Grimes & Company first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $19.9M in Q4 2021. 543 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Grimes & Company held 106,242 shares of Novo Nordisk worth $5.09M as of Q2 2026.
  • Grimes & Company bought 1,134 Novo Nordisk shares in Q2 2026, an estimated $48.7K.
  • Novo Nordisk made up 0.11% of Grimes & Company's portfolio in Q2 2026, its #122 holding.
  • Grimes & Company first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • Grimes & Company's Novo Nordisk position peaked at $19.9M in Q4 2021.
  • 543 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.